Although, MG132 treatment alone per se caused death in cervical cancer cells, the elevated level of Fas (in target cells) because of blockade in degradation enables the FasL (elevated upon MMC treatment in effector cells) to trigger enhanced killing in target cells. This evidence concerns the gene FAS and cervical cancer.